140 related articles for article (PubMed ID: 19500259)
1. Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis.
Odabasi Z; Paetznick VL; Rodriguez JR; Chen E; Rex JH; Leitz GJ; Ostrosky-Zeichner L
Mycoses; 2010 Sep; 53(5):438-42. PubMed ID: 19500259
[TBL] [Abstract][Full Text] [Related]
2. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
3. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
4. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans.
Jin J; Guo N; Zhang J; Ding Y; Tang X; Liang J; Li L; Deng X; Yu L
Lett Appl Microbiol; 2010 Sep; 51(3):351-7. PubMed ID: 20681969
[TBL] [Abstract][Full Text] [Related]
5. Azole resistance in Candida albicans.
Smith KJ; Warnock DW; Kennedy CT; Johnson EM; Hopwood V; Van Cutsem J; Vanden Bossche H
J Med Vet Mycol; 1986 Apr; 24(2):133-44. PubMed ID: 3014106
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study.
Lee MK; Kim HR; Kang JO; Kim MN; Kim EC; Kim JS; Kim JJ; Park YJ; Song W; Shin JH; Lee KM; Lee NY; Lee M; Lee WG; Lee CK; Lee HJ; Chang CL; Choi TY
Mycoses; 2007 Mar; 50(2):148-9. PubMed ID: 17305780
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antifungal effect of lactoferrin with azole antifungals against Candida albicans and a proposal for a new treatment method for invasive candidiasis.
Kobayashi T; Kakeya H; Miyazaki T; Izumikawa K; Yanagihara K; Ohno H; Yamamoto Y; Tashiro T; Kohno S
Jpn J Infect Dis; 2011; 64(4):292-6. PubMed ID: 21788703
[TBL] [Abstract][Full Text] [Related]
8. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens.
Yenişehirli G; Bulut Y; Güven M; Günday E
J Laryngol Otol; 2009 Sep; 123(9):978-81. PubMed ID: 19454132
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance genes and trailing growth in Candida albicans isolates.
Lee MK; Williams LE; Warnock DW; Arthington-Skaggs BA
J Antimicrob Chemother; 2004 Feb; 53(2):217-24. PubMed ID: 14688046
[TBL] [Abstract][Full Text] [Related]
11. Effect of ketoconazole, itraconazole and fluconazole on the gastrointestinal colonization of mice by Candida albicans.
Samonis G; Maraki S; Hajiioannou I; Chatzinikolaou I; Rolston KV; Bodey GP; Kontoyiannis DP
J Chemother; 2001 Feb; 13(1):66-9. PubMed ID: 11233803
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts.
Mondello F; De Bernardis F; Girolamo A; Salvatore G; Cassone A
J Antimicrob Chemother; 2003 May; 51(5):1223-9. PubMed ID: 12668571
[TBL] [Abstract][Full Text] [Related]
15. Impact of endpoint definition on the outcome of antifungal susceptibility tests with Candida species: 24- versus 48-h incubation and 50 versus 80% reduction in growth.
St-Germain G
Mycoses; 2001; 44(1-2):37-45. PubMed ID: 11398639
[TBL] [Abstract][Full Text] [Related]
16. Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis.
Wang Y; Jia XM; Jia JH; Li MB; Cao YY; Gao PH; Liao WQ; Cao YB; Jiang YY
Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):e40-6. PubMed ID: 19413603
[TBL] [Abstract][Full Text] [Related]
17. Azole resistant Candida glabrata vulvovaginitis treated with boric acid.
Savini V; Catavitello C; Bianco A; Balbinot A; D'Antonio F; D'Antonio D
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):112. PubMed ID: 19619928
[No Abstract] [Full Text] [Related]
18. Comparison between efficacy of allicin and fluconazole against Candida albicans in vitro and in a systemic candidiasis mouse model.
Khodavandi A; Alizadeh F; Harmal NS; Sidik SM; Othman F; Sekawi Z; Jahromi MA; Ng KP; Chong PP
FEMS Microbiol Lett; 2011 Feb; 315(2):87-93. PubMed ID: 21204918
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
20. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
